New antibody combo targets Hard-to-Treat cancers
NCT ID NCT05753722
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug called PRTH-101, alone or with an existing immunotherapy (pembrolizumab), in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The study will enroll about 270 people and focus on safety, dosing, and how the drug moves through the body. It is not yet known if PRTH-101 will shrink tumors or improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PRTH-101 (a lab-made antibody) and pembrolizumab (an immunotherapy drug)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial, so the main goal is safety, not effectiveness. The drug may not work or could cause serious side effects. Only a small number of people will be tested.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Honor Health Research Institute
RECRUITINGScottsdale, Arizona, 85258, United States
Contact
Contact
-
Mass General Cancer Center
RECRUITINGBoston, Massachusetts, 02114, United States
Contact
Contact
-
NEXT Houston
RECRUITINGHouston, Texas, 77054, United States
Contact
Contact
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
Contact
-
Next Oncology
RECRUITINGIrving, Texas, 75039, United States
Contact
Contact
-
Next Oncology
RECRUITINGFairfax, Virginia, 22031, United States
Contact
Contact
-
Providence Cancer Institute Franz Clinic
RECRUITINGPortland, Oregon, 97213, United States
Contact
Contact
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact
-
University of Pittsburgh Medical Center Hillman Cancer Center
COMPLETEDPittsburgh, Pennsylvania, 15232, United States
-
Vanderbilt-Ingram Cancer Center
RECRUITINGNashville, Tennessee, 27232, United States
Contact
Contact
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06511, United States
Contact
Contact